Sign up to save your podcasts
Or
Share What’s Material in ESG for Biopharma Firms?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
What’s Material in ESG for Biopharma Firms?
For biopharma companies, ESG commitments can look considerably different from other sectors. We spoke with the team of ESG leads at Gilead Sciences to understand the five key components driving its ESG strategy, how it’s evolved and how it impacts their business.
View all episodes
By RBC Capital Markets
5
1212 ratings
For biopharma companies, ESG commitments can look considerably different from other sectors. We spoke with the team of ESG leads at Gilead Sciences to understand the five key components driving its ESG strategy, how it’s evolved and how it impacts their business.
More shows like Pathfinders in Biopharma
View all
Motley Fool Money
3,235 Listeners
WSJ Your Money Briefing
1,724 Listeners
Exchanges
969 Listeners
Odd Lots
1,980 Listeners
WSJ Tech News Briefing
1,658 Listeners
The a16z Show
1,100 Listeners
The Long Run with Luke Timmerman
127 Listeners
The Readout Loud
337 Listeners
Wall Street Breakfast
1,045 Listeners
Thoughts on the Market
1,307 Listeners
The Journal.
6,120 Listeners
BioCentury This Week
35 Listeners
RBC's Markets in Motion
42 Listeners
Biotech Hangout
21 Listeners
Industries in Motion
10 Listeners
Powering Sustainable Ideas
0 Listeners
The Markets
83 Listeners
Strategic Alternatives
18 Listeners
The Top Line
15 Listeners
Macro Minutes
3 Listeners